Vicore acquiers INIM


Vicore Pharma Holding AB (publ) has entered into an agreement with HealthCap VII LP regarding the acquisition of INIM Pharma AB. Through the acquisition, a leading drug developing company focusing on severe lung diseases will be established.

Vicore is a biotech company focused on helping patients who suffer from rare diseases where there is currently no satisfactory treatment. Vicore´s focus is on the development of orphan drugs in fibrotic diseases.

INIM develops a local treatment of severe interstitial diseases such as IPF in collaboration with Nanologica AB, where their drug delivery technology is applied on validated immunomodulatory drugs.

Vicore acquires INIM through an issue in kind where Vicore issues new shares as compensation for all outstanding shares in INIM. The intention is to resolve on the issue in kind and pre-emption rights issue at an extraordinary general meeting in August.

MAQS Advokatbyrå was the legal advisor of Vicore with a team consisting of Niklas Eskilsson, Mikael Kowal, Lars Odinge and David Karlsson.